|
|
Volumn 128, Issue 7, 2005, Pages 1769-1770
|
|
Valdecoxib withdrawal leaves pain relief treatment gap
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CELECOXIB;
CYCLOOXYGENASE 2 INHIBITOR;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PLACEBO;
ROFECOXIB;
VALDECOXIB;
ACUTE DISEASE;
ADVISORY COMMITTEE;
ANALGESIA;
ARTHRALGIA;
CARDIOVASCULAR RISK;
COLON POLYP;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG DOSE REGIMEN;
DRUG EFFECT;
DRUG EFFICACY;
DRUG FATALITY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG LABELING;
DRUG MARKETING;
DRUG MECHANISM;
DRUG PACKAGING;
DRUG SAFETY;
DRUG SELECTIVITY;
DRUG WITHDRAWAL;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL HEMORRHAGE;
HEART INFARCTION;
HUMAN;
LOW DRUG DOSE;
NOTE;
PAIN;
POSTOPERATIVE PAIN;
PRIORITY JOURNAL;
RECURRENT DISEASE;
RHEUMATOID ARTHRITIS;
RISK ASSESSMENT;
STATISTICAL SIGNIFICANCE;
STROKE;
|
|
EID: 20444456954
PISSN: 00165085
EISSN: None
Source Type: Journal
DOI: 10.1053/j.gastro.2005.05.023 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|